Cargando…

Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design

OBJECTIVE: The purpose of the trial was to examine the impact of inhaled human insulin (INH) on patient or physician willingness to adopt insulin after oral diabetes agent failure. RESEARCH DESIGN AND METHODS: The EXPERIENCE trial was a one-year randomized controlled trial conducted at primary, seco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strack, Thomas, Martinez, Luc, Del Prato, Stefano, Blonde, Larry, Göke, Burkhard, Woo, Vincent, Millward, Ann, Gomis, Ramon, Canovatchel, Bill, Lawrence, David, Freemantle, Nick
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048012/ https://www.ncbi.nlm.nih.gov/pubmed/21437114

Ejemplares similares

Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme
por: Blonde, Lawrence, et al.
Publicado: (2021)

Will availability of inhaled human insulin (Exubera(®)) improve management of type 2 diabetes? The design of the Real World trial
por: Freemantle, Nick, et al.
Publicado: (2006)

Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study
por: Home, Philip, et al.
Publicado: (2018)

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
por: Vilsbøll, Tina, et al.
Publicado: (2016)

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
por: Blonde, Lawrence, et al.
Publicado: (2018)

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal
por: Gupta, Vishal, et al.
Publicado: (2017)

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
por: Skolnik, Neil, et al.
Publicado: (2021)

Comment on “a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes”
por: Freemantle, Nick, et al.
Publicado: (2019)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
por: Blonde, Lawrence, et al.
Publicado: (2015)

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes
por: Woerle, Hans Juergen, et al.
Publicado: (2012)

Glycemic Control and Awareness of Insulin Therapy
por: Pashchenko, Yegor, et al.
Publicado: (2021)

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
por: Rosenstock, Julio, et al.
Publicado: (2021)

Impact of Alcohol on Glycemic Control and Insulin Action
por: Steiner, Jennifer L., et al.
Publicado: (2015)

Insulin glargine 300 U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial
por: Meneghini, Luigi, et al.
Publicado: (2020)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Acute effect of meal glycemic index and glycemic load on blood glucose and insulin responses in humans
por: Galgani, José, et al.
Publicado: (2006)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
por: Blonde, Lawrence, et al.
Publicado: (2021)

Achieving glycemic control with intensive insulin therapy in the ICU
por: Vakalos, A, et al.
Publicado: (2008)

The Role of Soluble Corn Fiber on Glycemic and Insulin Response
por: Tan, Wei Shuan Kimberly, et al.
Publicado: (2020)

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
por: Buse, John B., et al.
Publicado: (2010)

Association of Dietary Glycemic Index, Glycemic Load, Insulin Index, and Insulin Load with Bacterial Vaginosis in Iranian Women: A Case-Control Study
por: Noormohammadi, Morvarid, et al.
Publicado: (2022)

The Impact of Insulin-Induced Lipodystrophy on Glycemic Variability in Pediatric Patients with Type 1 Diabetes
por: Lombardo, Fortunato, et al.
Publicado: (2022)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Characterization of the insulin sensitivity of ghrelin receptor KO mice using glycemic clamps
por: Qi, Yong, et al.
Publicado: (2011)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus
por: Chien, Ming‐Nan, et al.
Publicado: (2016)

Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes
por: Granata, Joseph A., et al.
Publicado: (2015)

Barriers to Achieving Glycemic Targets: Who Omits Insulin and Why?
por: Weinger, Katie, et al.
Publicado: (2010)

Efficacy of insulin lispro in improving glycemic control in gestational diabetes
por: Deepaklal, M.C., et al.
Publicado: (2014)

Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes
por: Henao-Carrillo, Diana Cristina, et al.
Publicado: (2018)

Synthesis and Evaluation of the Insulin–Albumin Conjugate with Prolonged Glycemic Control
por: Rao, Shrilakshmi Sheshagiri, et al.
Publicado: (2022)

Bistable insulin response: The win-win solution for glycemic control
por: Akhtar, Javed, et al.
Publicado: (2022)

Metabolic Adaptation in Lactation: Insulin-dependent and -independent Glycemic Control
por: Fu, Ling, et al.
Publicado: (2022)

Effect of diet on postprandial glycemic and insulin responses in healthy dogs
por: Vastolo, Alessandro, et al.
Publicado: (2023)

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
por: Blonde, Lawrence, et al.
Publicado: (2020)

Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet
por: Becker, Melanie, et al.
Publicado: (2010)

A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes
por: Freemantle, N, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s2f6ipr9vghdn9dv6hpijhtdu1